Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

20 May 2003

Late relapse of hepatoblastoma in children –case report

E. Rogowska, M. Rychłowska, W. Woźniak

Med Sci Monit 2003; 9(2): 15- :: ID: 15271

Abstract

Background:We would like to present two patients in our hospital for hepatoblastoma,both with late relapse diagnosed.Case Report:Patient No 1.3 8/12-year old girl was treated for liver left lobe hepatoblastoma at the age of 15 months.The level of AFP before the treatment ’s beginning was 428 400 JU/ml.The tumor was situated in the whole epigastric region and was also palpable in pelvis.The patient was qualified to the chemotherapy according to SIOPEL protocol.She received 3 course of treatment:1CDDP-80 mg/sqm,and 3 courses of PLADO (ADM/CDDP).AFP decreased to the level of 199.76 IU/ml. Afterwards the surgical procedure of the tumor ’s resection was perfomed. Histological examination has proved total tumor necrosis;alive neoplastic cells were found only in satellite module and in the lymph node.Application of 2 course of PLADO followed the operation and led to treatment completion.14 months after the treatment ’s end the local relapse in the left lobe of the liver with increase of AFP to the level of 767,79 was diagnosed. Chemotherapy with high doses of CTX (due to SIOPEL protocol)was introduced.There was no response to this treatment.Therefore chemotherapy was changed –the patient received 1 course of CBDCA/VP-16 –without any response again.Hence the chemotherapy was changed again –2 courses of ADM/CDDP were administred.The level of AFP decreased, which allowed performing a surgical resection of the right liver lobe.Histological examination has proved live neoplastic cells in the whole tumor; neoplastic cells were also present in the blood vessels.Due to this result the treatment was changed again –the patient received combined chemotherapy:CDDP, 5FU,VCR.The girl received 2 courses of this therapy and still is being treated in our hospital. Patient No 2.4-year old girl treated from the age of 12 months or left liver lobe hepatoblastoma.The level of AFP before treatment ’s beginning was 595 000 UI/ml.The tumor was diagnosed as inoperalbc.The patient was qualified to the chemotherapy according to SIOPEL protocol.She received 5 course of CDDP in dose of 80 mg/m 2 and 3 courses of PLADO. AFP level decreased to 4 000 IU/ml.The surgical procedure of the tumor ’s resection was perfomed.Histological examination has proved tumor necrosis in 50%,the operation waw not adical,neoplastic cells were present in blood vessels. Chemotherapy was being continued and the girl received 4 courses of PLADO,what completed the treatment.35 months after the treatment ’s and a relapse in the right lobe of the liver was diagnosed.Additionally metastases in the right lung was suspected.AFP –46 020 IU/ml.Chemotherapy with high doses of CTX according to SIOPEL was administered.After 2 courses there was no response to the reatment.Chemotherapy was changed –the patient received 1 course of CBDCA/VP-16- also without any response.Afterwards chemotherapy with ADM/CDDP according to SIOPEL was administred.A positive response towards treatment has been obtained –AFP decreased to the level of 845 IU/ml.The patient is still treated in our hospital.Conclusions:1.The patient after completed treatment for hepatoblastoma should be observed for the long time because of a high risk of late relapses. 2.If the radicality of surgery procedure is doubtful it seems to be advisable to adhibit local radiotherapy.

Keywords:

0 Comments

Editorial

01 July 2022 : Editorial  

Editorial: World Health Organization (WHO) Variants of Concern Lineages Under Monitoring (VOC-LUM) in Response to the Global Spread of Lineages and Sublineages of Omicron, or B.1.1.529, SARS-CoV-2

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.937676

Med Sci Monit 2022; 28:e937676

SARS-CoV-2/COVID-19

27 June 2022 : Clinical Research  

Shoulder Injury Related to Vaccine Administration (SIRVA) in 16 Patients Following COVID-19 Vaccination Who...

Med Sci Monit In Press; DOI: 10.12659/MSM.937430  

27 May 2022 : Clinical Research  

Factors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19)

Med Sci Monit 2022; 28:e936547

In Press

05 Jul 2022 : Clinical Research  

Attention-Deficit/Hyperactivity Disorder (ADHD) and Time Perception in Adults: Do Adults with Different ADH...

Med Sci Monit In Press; DOI: 10.12659/MSM.936849  

01 Jul 2022 : Clinical Research  

Does Early-Period Patient Dissatisfaction Turn Into Satisfaction Over Time After Total Knee Replacement?

Med Sci Monit In Press; DOI: 10.12659/MSM.936792  

30 Jun 2022 : Laboratory Research  

Bcl-2 19-kDa Interacting Protein 3 (BNIP3)-Mediated Mitophagy Attenuates Intermittent Hypoxia-Induced Human...

Med Sci Monit In Press; DOI: 10.12659/MSM.936760  

30 Jun 2022 : Clinical Research  

Antioxidant System and Ions Concentrations After Femoral Neck and Resurfacing Hip Arthroplasty

Med Sci Monit In Press; DOI: 10.12659/MSM.936335  

Most Viewed Current Articles

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750